0001262463-20-000183.txt : 20200507 0001262463-20-000183.hdr.sgml : 20200507 20200507164410 ACCESSION NUMBER: 0001262463-20-000183 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 37 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200507 DATE AS OF CHANGE: 20200507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Global Wholehealth Partners Corp CENTRAL INDEX KEY: 0001598308 STANDARD INDUSTRIAL CLASSIFICATION: OIL AND GAS FIELD EXPLORATION SERVICES [1382] IRS NUMBER: 462316220 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-56035 FILM NUMBER: 20857184 BUSINESS ADDRESS: STREET 1: 2227 AVENIDA OLIVA CITY: SAN CLEMENTE STATE: CA ZIP: 92673 BUSINESS PHONE: (714) 392-4112 MAIL ADDRESS: STREET 1: 2227 AVENIDA OLIVA CITY: SAN CLEMENTE STATE: CA ZIP: 92673 FORMER COMPANY: FORMER CONFORMED NAME: Texas Jack Oil & Gas Corp DATE OF NAME CHANGE: 20140127 10-Q 1 gwhp33120q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2020

 

oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________ to ___________

 

Commission file number 000-56035

 

GLOBAL WHOLEHEALTH PARTNERS CORPORATION

(Exact name of registrant as specified in its charter)

 

Nevada  

46-2316220 

(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)

 

 

  

 

 

2227 Avenida Oliva    
San Clemente, California   92673
(Address of principal executive offices)   (Zip Code)

 

(714) 392-9752

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No o

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐   Accelerated filer  ☐
Non-accelerated filer ☐   Smaller reporting company ☒
Emerging growth company ☐      

 

 1 
 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in 12b-2 of the Exchange Act). Yes o No ☒

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 58,116,358 shares of common stock, par value $0.001, were outstanding on May 7, 2020.

 

 

 

 

 

 

 

 

 

 

 

 

 

 2 
 

GLOBAL WHOLEHEALTH PARTNERS CORPORATION

FORM 10-Q

 

For the Quarterly Period Ended March 31, 2020

 

Table of Contents

 

PART I. FINANCIAL INFORMATION  
       
  Item 1. Financial Statements (Unaudited) 4
    Balance Sheets 4
    Statements of Operations 5
    Statements of Stockholders’ Equity 6
    Statements of Cash Flows 7
    Notes to Financial Statements 8
       
  Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 12
       
  Item 4. Controls and Procedures 18
       
PART II. OTHER INFORMATION  
     
  Item 1A. Risk Factors 19 
       
  Item 5. Other Information 19 
       
  Item 6. Exhibits 20 
       

  

 Signatures 21

 

 3 
 

PART I — FINANCIAL INFORMATION 

Item 1. Financial Statements (Unaudited)

 

GLOBAL WHOLEHEALTH PARTNERS CORPORATION      
CONSOLIDATED BALANCE SHEETS
       
   March 31,  June 30,
   2020  2019
   (Unaudited)   
ASSETS      
Current assets:          
Cash  $668   $19,918 
Inventory   23,372    —   
Total current assets   24,040    19,918 
Total assets  $24,040   $19,918 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
           
Current liabilities:          
Related party note  $62,875   $—   
Related party advances   1,500    —   
Accounts payable and accrued liabilities   1,372    100 
Total current liabilities   65,747    100 
Total liabilities   65,747    100 
           
Commitments and contingencies          
           
Stockholders' equity (deficit):          
Preferred stock; $0.001 par value, 10,000,000 shares authorized, no shares issued or outstanding at March 31, 2020 and June 30, 2019, respectively   —      —   
Common stock; $0.001 par value, 400,000,000 shares authorized, 58,116,358 and 56,116,358 shares issued and outstanding at March 31, 2020 and June 30, 2019, respectively   58,116    56,116 
Additional paid-in capital   444,784    426,784 
Retained deficit   (544,607)   (463,082)
Total stockholders' equity   (41,707)   19,818 
Total liabilities and stockholders' equity  $24,040   $19,918 
           
(See accompanying notes to consolidated financial statements)

 4 
 

GLOBAL WHOLEHEALTH PARTNERS CORPORATION      

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2020 AND 2019

       

    

Three Months Ended

March 31,

   

Nine Months Ended

March 31,

    2020    2019    2020    2019 
                     
                     
Revenue  $—     $—     $—     $—   
                     
Operating expense                    
Professional fees   9,000    6,738    44,900    6,738 
Research and development   443,750    —      443,750    —   
Selling, general and administrative   2,629    2,270    36,625    2,870 
Total operating expense   455,379    9,008    525,275    9,608 
Loss from operations   (455,379)   (9,008)   (525,275)   (9,608)
Other income                    
Gain on forgiveness of liabilities   443,750    —      443,750    —   
Net loss  $(11,629)  $(9,008)  $(81,525)  $(9,608)
                     
Basic and Diluted Loss per Common Share  $(0.00)  $(0.17)  $(0.00)  $(0.18)
                     
Weighted average number of common shares outstanding - basic and diluted   58,116,358    52,358    57,343,755    52,358 
                     
                     
(See accompanying notes to consolidated financial statements) 

 

 5 
 

GLOBAL WHOLEHEALTH PARTNERS CORPORATION        
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)
 
FOR THE NINE MONTHS ENDED MARCH 31, 2020                 
     Common Stock     

Additional

Paid-in

    Retained    

Total

Stockholders’

 
     Shares      Amount     Capital    Deficit    Deficit 
BALANCE JULY 1, 2019   56,116,358   $56,116   $426,784   $(463,082)  $19,818 
                          
   Net loss for the three months ended September 30, 2019   —      —      —      (18,798)   (18,798)
Balance, September 30, 2019   56,116,358    56,116    426,784    (481,880)   1,020 
                          
Common stock issued to related party for cash at $0.01 per share   2,000,000    2,000    18,000    —      20,000 
   Net loss for the three months ended December 31, 2019   —      —      —      (51,098)   (51,098)
Balance, December 31, 2019   58,116,358    58,116    444,784    (532,978)   (30,078)
                          
   Net loss for the three months ended March 31, 2020   —      —      —      (11,629)   (11,629)
Balance, March 31, 2020   58,116,358   $58,116   $444,784   $(544,607)  $(41,707)
                          
FOR THE NINE MONTHS ENDED MARCH 31, 2019                   
                          
BALANCE JULY 1, 2018   52,358   $52   $430,748   $(432,215)  $(1,415)
                          
   Net loss for the three months ended September 30, 2018   —      —      —      (300)   (300)
Balance, September 30, 2018   52,358    52    430,748    (432,515)   (1,715)
                          
   Net loss for the three months ended December 31, 2018   —      —      —      (300)   (300)
Balance, December 31, 2018   52,358    52    430,748    (432,815)   (2,015)
                          
   Net loss for the three months ended March 31, 2019   —      —      —      (9,008)   (9,008)
Balance, March 31, 2019   52,358   $52   $430,748   $(441,823)  $(11,023)
                          
(See accompanying notes to consolidated financial statements)

 

 6 
 

GLOBAL WHOLEHEALTH PARTNERS CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

FOR THE NINE MONTHS ENDED MARCH 31, 2020 AND 2019
           
    Nine Months Ended March 31,
    2020    2019 
Cash flows from operating activities          
Net loss  $(81,525)  $(9,608)
Adjustments to reconcile net loss to net cash flows used in operating activities:          
Common stock issued for services   —      —   
Common stock issued for debt settlement   —      —   
Changes in operating assets and liabilities:          
(Increase) decrease in inventory   (23,372)   —   
Increase (decrease) in related party advances   1,500    10,923 
Increase (decrease) in accounts payable and accrued expenses   1,272    (1,315)
Net cash flows from operating activities   (102,125)   —   
           
Cash flows from financing activities          
Cash for common shares of stock   20,000      
Proceeds from related party note, net   62,875      
Net cash flows from  financing activities   82,875    —   
           
Change in cash   (19,250)   —   
           
Cash at beginning of period   19,918    —   
           
Cash at end of period  $668   $—   
           
Supplemental disclosure of cash flow information:          
Interest paid in cash  $—     $—   
Income taxes paid in cash  $—     $—   
           
(See accompanying notes to consolidated financial statements)

 

 7 
 

 GLOBAL WHOLEHEALTH PARTNERS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2020 AND 2019

 

NOTE 1 – Basis of Presentation, Organization and Going Concern

 

Basis of Presentation

 

The accompanying unaudited interim condensed consolidated financial statements of Global WholeHealth Partners Corporation and Subsidiary (the “Company”) as of March 31, 2020, and for the three and nine months ended March 31, 2020 and 2019, include the accounts of the Company and its wholly-owned and controlled subsidiary, Global WholeHealth Partners Corp, a private Wyoming corporation, and have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”), for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted.

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results may differ from those estimates. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10 for the year ended June 30, 2019.In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) necessary for the fair presentation of the Company’s financial position as of December 31, 2019, results of operations for the three and nine months ended March 31, 2020 and 2019, and stockholders’ equity and cash flows for the three and nine months ended March 31, 2020 and 2019. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.

 

Organization

 

Global WholeHealth Partners Corporation was incorporated on March 7, 2013 in the State of Nevada under the name Texas Jack Oil and Gas Corp. On May 9, 2019, the Company amended its Articles of Incorporation to effect a change of name to Global WholeHealth Partners Corporation to align the company name with its focus on health care related development and products. The Company’s ticker symbol changed to GWHP.

 

The Company was originally organized for the purpose of exploration of Oil and Gas. However, the Company was unable to establish an oil and gas concern and was abandoned in 2016. On February 27, 2019, the Clark County District Court of Nevada appointed Barbara Bauman as custodian to the Company. The custodian reestablished the Company in good standing.

 

On May 9, 2019, the Board reverse split (1-for-500) the outstanding Common Shares of 58,172,000 to 116,358 shares.

 

May 23, 2019, the Company and LionsGate Funding Group LLC (“LionsGate”), owner of a majority of the Company’s outstanding common stock as of May 23, 2019, entered into a Stock Sale and Purchase Agreement (the “SPA”) which closed on June 27, 2019. Pursuant the SPA, the Company issued 56,000,000 shares of common stock to LionsGate in exchange for 100% of their interests in Global WholeHealth Partners Corp., a private Wyoming corporation incorporated on April 9, 2019 (“Global Private”). Global Private has contacts with suppliers and contract manufacturers in the In vitro diagnostic industry, with rights to sell rapid diagnostic tests, such as the following 6 minute rapid whole blood Ebola Test, 6 minute whole blood Zika test, 8 minute whole blood rapid TB test and 75 plus other tests more than 40 which are FDA approved. Due to the common control of the Company and Global Private, pursuant to ASC 805-50-25, “Transactions Between Entities Under Common Control”, the SPA was accounted for as a transfer of the carrying amounts of assets and liabilities under the predecessor value method of accounting. Financial statement presentation under the predecessor values method of accounting as a result of a business combination between entities under common control requires the receiving entity (i.e., the Company) to report the results of operations as if both entities had been combined as of the beginning of the periods presented. The consolidated financial statements include both entities’ full results since the inception of Global Private.

 

 8 
 

Going Concern

 

The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs to allow it to continue as a going concern. As of March 31, 2020, the Company had an accumulated deficit of $544,607. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

 

In view of these conditions, the ability of the Company to continue as a going concern is in doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. Historically, the Company has relied upon internally generated funds, and funds from the sale of stock, issuance of promissory notes and loans from its shareholders and private investors to finance its operations and growth. Management is planning to raise necessary additional funds for working capital through loans and/or additional sales of its common stock. However, there is no assurance that the Company will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should the Company be unable to raise this amount of capital its operating plans will be limited to the amount of capital that it can access. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements.

 

NOTE 2 – Summary of Significant Accounting Policies

 

Principles of Consolidation

 

Global WholeHealth Partners Corp, a private Wyoming corporation was incorporated on April 9, 2019 to receive private investor funds and aggregate certain in vitro diagnostic assets.

 

These consolidated financial statements presented are those of Global WholeHealth Partners Corporation and its wholly owned subsidiary, Global Private. All significant intercompany balances and transactions have been eliminated.

 

Accounting estimates

 

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates.

 

Cash and cash equivalents

 

The Company considers all highly liquid instruments purchased with an original maturity of three months or less and money market accounts to be cash equivalents.

 

 9 
 

Income Taxes

 

The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively.

 

Fair Value Measurements

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilizes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

During the periods covered by this report, the Company did not have any assets or liabilities that were required to be measured at fair value on a recurring basis or on a non-recurring basis.

 

Fair Value of Financial Instruments

 

The Company’s financial instruments consist of cash, accounts payable and accrued expenses. The carrying amounts of the Company’s financial instruments approximate fair value because of the short term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect those estimates. We do not hold or issue financial instruments for trading purposes, nor do we utilize derivative instruments.

 

Net Income (Loss) Per Share

 

The computation of basic earnings per share (“EPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common shares that would be issued assuming the exercise of all potentially dilutive common shares outstanding using the treasury stock method. The Company had no potentially dilutive securities as of December 31, 2019.

 

New Accounting Pronouncements

 

Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification.

 

We review new accounting standards as issued. Although some of these accounting standards issued or effective after the end of our previous fiscal year may be applicable to us, we have not identified any standards that we believe merit discussion. We believe that none of the new standards will have a significant impact on our consolidated financial statements.

 

 10 
 

NOTE 3 – Stockholder’s Equity

 

Preferred Stock

 

The Company has Preferred stock: $0.001 par value; 10,000,000 shares authorized with no shares issued and outstanding.

 

Common Stock

 

The Company has 400,000,000 shares of Common Stock authorized of which 58,116,358 and 56,116,358 shares were issued and outstanding as of March 31, 2020 and June 30, 2019, respectively. During the nine months ended March 31, 2020, the number of shares increased by 2,000,000 as a result of the Company selling 2,000,000 shares at $0.01 per share to LionsGate in exchange for cash of $20,000.

 

NOTE 4 – Related Party Transactions

 

During the nine months ended March 31, 2020, the Company received $20,000 upon the sale of 2,000,000 shares of common stock to LionsGate for $0.01 per share.

 

From time-to-time the Company receives shareholder advances to cover operating costs which are reflected on the balance sheet as related party advances. During the three months ended March 31, 2020, LionsGate provided advances totaling $455,950 which was used to pay professional fees of $11,100, research studies for the development of its CoVid-19 tests of $443,750 and general costs of $1,100. During the nine months ended March 31, 2020, LionsGate provided advances totaling $506,625 which was used to pay professional fees of $46,000, research studies for the development of CoVid-19 tests of $443,750 and general costs of $16,875.

 

During the three months ended March 31, 2020, the Company paid $431,250 to Pan Probe Biotech to perform studies in validation of the Company’s CoVid-19 tests. Dr. Shujie Cui is the Company’s Chief Science Officer and 100% owner of Pan Probe.

 

NOTE 5 – Promissory Note

 

On March 29, 2020, the Company issued a Promissory Note (the “Note”) to LionsGate in the amount of $506,625 which was equivalent to the advances made to the Company up to March 29, 2020. On March 30, 2020, LG decided it would be in the best interests of the Company to forgive the portion of the Note related to testing costs which totaled $443,750. As a result, the Company recognized $443,750 of other income for the three and six months ended March 31, 2020 leaving a Note balance of $62,875. The terms of the Note provide total funding of up to $585,000 or an additional $78,375. The Note bears interest at the rate of 5% per annum and the principal and interest is due and payable in full in 90 days on June 30, 2020. If not paid within the 90 days a 5% penalty will be added to the Note and the term will extend for an additional 90 days.

 

The Note was issued by the Company under the exemption from registration afforded by Section 4(a)(2) of the Securities Act, as amended and/or Regulation D promulgated thereunder, as the securities were issued to accredited investors, without a view to distribution, and were not issued through any general solicitation or advertisement.

 

NOTE 6 – Subsequent Events

 

Management has reviewed material events subsequent of the period ended March 31, 2020 and prior to the filing of our consolidated financial statements in accordance with FASB ASC 855 “Subsequent Events”.

 

The recent outbreak of the novel coronavirus CoVid-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies and created uncertainty regarding potential impacts to the Company’s employees and R&D activities. The CoVid-19 pandemic has impacted and could further impact the Company’s operations and the operations of the Company’s vendors as a result of quarantines, facility closures, and travel and logistics restrictions. The extent to which the CoVid-19 pandemic impacts the Company’s business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to the duration, spread, severity, and impact of the CoVid-19 pandemic, the effects of the CoVid-19 pandemic on the Company’s customers, suppliers, and vendors and the remedial actions and stimulus measures adopted by local, state and federal governments, and to what extent normal economic and operating conditions can resume. Even after the CoVid-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Therefore, the Company cannot reasonably estimate the impact at this time.

 

 11 
 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

This Report on Form 10-Q contains forward-looking statements which involve assumptions and describe our future plans, strategies, and expectations, and are generally identifiable by use of words such as “may,” “will,“ “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project,” or the negative of these words or other variations on these words or comparable terminology. These statements are expressed in good faith and based upon a reasonable basis when made, but there can be no assurance that these expectations will be achieved or accomplished.

 

Such forward-looking statements include statements regarding, among other things, (a) the potential markets for our products, our potential profitability, and cash flows, (b) our growth strategies, (c) anticipated trends in the in-vitro diagnostics industry, (d) our future financing plans, and (e) our anticipated needs for working capital. This information may involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from the future results, performance, or achievements expressed or implied by any forward-looking statements. These statements may be found under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” as well as in this Form 10-Q generally. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors, including, without limitation, the matters described in this Form 10-Q generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur. In addition to the information expressly required to be included in this filing, we will provide such further material information, if any, as may be necessary to make the required statements, in light of the circumstances under which they are made, not misleading.

 

Although forward-looking statements in this report reflect the good faith judgment of our management, forward-looking statements are inherently subject to known and unknown risks, business, economic and other risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report, other than as may be required by applicable law or regulation. Readers are urged to carefully review and consider the various disclosures made by us in our filings with the Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect our actual results may vary materially from those expected or projected.

 

Except where the context otherwise requires and for purposes of this Form 10-Q only, “we” “us“ “our“ “Company“ “our Company“ and “Global WholeHealth Partners” refer to Global WholeHealth Partners Corporation, a Nevada corporation.

 

Overview

 

The Company was founded to develop, manufacture and market in-vitro diagnostic (“IVD”) tests for over-the-counter (“OTC” or consumer), or consumer-use and point-of-care (“POC” or professional) which includes hospitals, physicians’ offices and medical clinics, including those within penal systems throughout the US and abroad. The Company currently manufactures and markets a range of diagnostic test kits for consumer use through OTC sales, and for use by health care professionals, generally located at medical clinics, physician offices and hospitals known POC, in the United States. These test kits are known as in-vitro diagnostic test kits or “IVD” products.

 

The Company believes, according to publicly available sources, that the IVD industry is a multi-billion dollar industry that is increasing each year. This assessment includes all laboratory hospital-based products, OTC devices, and rapid tests performed at the point-of-care. The Company believes that the following factors can be attributed to the increase in overall need and use of IVD test kits: an aging baby-boomer population; increasing healthcare costs; the ever-growing number of uninsured and under-insured in the U.S. and abroad; and a general increase in consumer awareness, in part due to the wealth of information available on the Internet. 

 12 
 

The concepts that distinguish POC technology—operation simple enough for non-laboratory users; little or no maintenance requirement; and rapid, reliable results—mean that it can be applied equally well in many non-clinical settings, such as the OTC market. As advances in medical technology increasingly make it possible to diagnose diseases and physiological conditions from ever-smaller amounts of body fluids, certain diseases and conditions that once required diagnosis by physicians and/or medical technicians inside hospital emergency rooms, exam rooms/bedside studies, or private clinics, can now also be done by inexpensive, easy-to-use diagnostic devices that consumers can use in the comfort and anonymity of their home. Today, the average pharmacy, whether a privately owned neighborhood store, or chain owned, has become an outlet for selling IVD test kits for in-home use.

  

All of the products we sell are manufactured in an FDA Approved Facility in the USA. An FDA Approved facility is a facility that meets Good Manufacturing Practices (“GMP”) with the FDA.

 

CoVid-19 / SARS2 Activities

 

In response to the CoVid-19 / SARS2 (“CoVid-19”) Pandemic, in early January 2020, the Company set out to test and perform the studies necessary to develop a Rapid Diagnostic Test (“RDT”) and Real Time Polymerase Chain Reaction Test (“RT-PCR”). During the quarter, the Company completed the testing necessary to develop both the RDT and RT-PCR tests. RDT test results are available in 10 minutes with an overall accuracy rate of 98%. The RT-PCR test looks for the E-Gene and RdRq-Gene markers and has proven to be 97% accurate. The test is able to be processed in any PCR machine and each test kit includes the required reagents.

 

On March 13, 2020 Charles Strongo, CEO filed on the behalf of the Company, the Pre Emergency Use Application (“PEUA”) with the FDA for the RT-PCR Test for CoVid-19. On March 15, 2020, the FDA sent an Official Acknowledgement letter accepting the Company’s application for the RT-PCR Test for CoViD-19. The Company is in the process of responding to FDA inquires.

 

On April 6, 2020, Mr. Strongo filed on the behalf of the Company a PEUA for the RDT for CoViD-19 test. On April 6th 2020, the FDA sent the Official Acknowledgement Letter accepting the Company’s Application for the RDT. The Company is in the process of responding to FDA inquires.

 

On April 13, 2020, the Department of NAVY ordered 1,000 RDT tests from the Company under the FDA March 16th guideline, which allows tests to be sold once a tests accuracy is demonstrated to be 90%+ and a PEUA has been filed with the FDA while working with the FDA for approval. The NAVY order was delivered on April 29, 2020 at the NAVY BASE at Point Loma.

 

The Company has sent RDT samples to 3rd party Labs for evaluations with positive feedback.

 

The Company anticipates near term sales of its RDT and PCR tests to various domestic and international private and public entities.

 

The Company is currently developing the next generation of RDT and Microwell CoVid-19 tests to achieve increased accuracy, remove all cross reactivity on the test itself and differentiate between the IgG and IgM antibodies which differentiation aids in an improved understanding of the stage of disease progression.

  

Industry

 

The use of diagnostics in quality measures often is supported by clinical practice guidelines. Of all the quality measures contained in The Healthcare Effectiveness Data and Information Set (“HEDIS”) is a widely used set of performance measures in the managed care industry, developed and maintained by the National Committee for Quality Assurance (“NCQA”) and The National Quality Measures Clearinghouse (“NQMC”). We identified guidelines specifically recommending diagnostic use in the NGC for 61.5% of those in HEDIS and 78.5% of those in the NQMC.

 

 13 
 

Of course, the development of measures for HEDIS, NQMC and other quality assessment initiatives is a relatively new process and represents only a sample of evidence-based use of diagnostics. Nevertheless, this analysis conveys the essential role of diagnostics in health care quality. Further, the incorporation of diagnostics into quality measures serves as a benchmark for assessing underuse of diagnostics and the health and economic impact of such underuse.

 

In its annual report on the state of health care quality in the US, NCQA assessed the impact of under-compliance with HEDIS measures, including those pertaining to diagnostics, on avoidable adverse health events, deaths and costs. Figure 7.7 below shows these impacts for measures pertaining to diagnostics used in breast cancer detection, cholesterol management, colorectal cancer screening and diabetes management.

 

Figure 7.7 Relationship between Application of Selected HEDIS Diagnostic Quality Measures and Avoidable Adverse Health Events, Deaths and Costs

 

 

HEDIS Quality Measure

 Percent National Under-use in HEDIS Compliant Health Plans

 

Estimated Annual Avoidable Adverse Health Events

 

Estimated Annual Avoidable Deaths

 

Estimated Annual Avoidable Costs

Breast cancer screening 19.3% 7,600 breast cancer 600–1,000 $ 48 million
(biopsy, needle   cases treated in Stage    
aspiration or   IV due to late    
mammography)   diagnosis    
Cholesterol management 48.9 14,600 major coronary events 6,900–17,000 $ 87 million
Colorectal cancer 51.9 20,000 cases of 4,200–6,300 $191 million
screening   colorectal cancer    
(FOBT or colonoscopy)   diagnosed/treated at a    
    later stage    

Diabetes management

(HbA1c control)

 20.2 14,000 heart attacks, strokes, or amputations 4,300–9,600 $573 million

 

549 State of health care quality: industry trends and analysis. Washington, DC: National Committee for Quality Trance, 2004.

 

These and other findings of the 2004 NCQA report on the state of health care quality demonstrate the potential for evidence-based use of diagnostics to improve health care quality and to avoid unnecessary adverse health events, deaths and costs. These studies are the most recent and as time has passed, we all understand that the cost of Health Care has gone up dramatically and therefore the savings to the health care industry is even greater than the studies show (See Figure 7.7 above).

 

Health care increasingly is subject to demands for improved health and quality of life and constraints on the spending required to deliver these improvements. In vitro diagnostics, henceforth in this report referred to as diagnostics, aid in responding to such demands by enabling accurate detection of health risks and disease at earlier stages and improving treatment and disease management, while diminishing subsequent health problems and their associated costs. Diagnostics serve a key role in the health value chain by influencing the quality of patient care, health outcomes, and downstream resource requirements.

 

From consumer-friendly at-home pregnancy and glucose monitoring tests to more complex automated laboratory-based systems, these tests are often first-line health decision tools. While diagnostics comprise less than 5% of hospital costs and about 1.6% of all Medicare costs, their findings influence as much as 60-70% of health care decision-making. The value of diagnostics accrues to not only clinicians and patients, but to health care managers, third-party payers, and quality assurance organizations that use diagnostic performance to measure and improve health care quality.

 

 14 
 

The following data have been culled from various publicly available sources that the Company believes to be accurate but cannot guarantee it. The Company has attempted to provide conservative statistics and believe that it is generally known that the market for IVD products is significant and is continuing to grow.

 

The pregnancy test is one of the primary home tests used in the world. The Company believes that approximately, 85,000 retail drug stores in the U.S. are selling over $900 million of pregnancy tests alone and continues to increase annually. Presently, it knows of five major manufacturers of this product.

 

The ovulation test market is generally estimated at $51 million annually and is growing annually. Presently, the Company is aware of four major brand companies that offer this test.

 

The glucose (diabetes) whole blood test is used to test for abnormal glucose blood levels. A significant number of individuals are affected in the United States with non-insulin dependent diabetes (Type II), many of whom are without knowledge of the disease. This disease, left untreated, can cause cardiovascular disorders and cataracts. With the explosive growth of childhood obesity and general poorer health on Americans, this test can saves thousands of lives.

 

As mentioned in the table 7.7: Diabetes management: There are 14,000 heart attacks, strokes, or amputations; 4,300–9,600 Deaths, but with Rapid Diagnostic Testing an annual avoidable cost of $573 million per year, and lives saved.

 

The Company’s most recent OTC product is its colorectal test (colon disorders). The Company estimates the demand for this test to increase with awareness of availability. It knows of only one other company that is currently offering this product. The colorectal Cancer screening tests helps detect the possibility of cancer early and can saves thousands of lives and millions of dollars. Colorectal cancer screening (FOBT) Fecal Occult Blood Test: 20,000 cases of colorectal cancer diagnosed/treated at a later stage and 4,200–6,300 deaths, but with Rapid Diagnostic Testing an annual avoidable cost of $191 million per year and lives saved.

 

The Company’s cholesterol OTC test and its cholesterol colorimetric POC test are available to test for abnormal levels of cholesterol in whole blood. There is evidence that a high blood cholesterol level increases the risk of developing arteriosclerosis, and with it the risk of coronary heart disease or stroke. This heart disease is the leading cause of death in the United States, as reported by the American Heart Association. Estimated Annual Avoidable Adverse Health Events are estimated to be approximately 14,600 with estimated annual avoidable deaths of approximately 6,900–17,000 from high Cholesterol. Rapid Diagnostic Tests taken by this populations would save an estimated $87 million per year and lives saved.

 

The market for drugs-of-abuse tests for the over-the-counter market is generally estimated to be one of the fastest growing markets of all IVD test products. At present, the Company believes that many law enforcement and governmental agencies are using laboratory testing facilities and must wait for results, often taking one week to ten days. The Company’s tests are completed onsite within ten minutes.

 

A significant number of people are infected by the H-Pylori bacteria, which are associated with ulcers. The Company’s H-Pylori test for the POC is one of its newest products.

 

All of the Company’s diagnostic tests, over 90 products are available for international distribution. The Company believes that its tests are excellent for distribution and use in underdeveloped countries because, unlike lab and other rapid diagnostic tests, its test kits do not need refrigeration and can withstand extended periods of excessive heat.

 

Competition

 

Several companies around the world carry similar products, typically comprised of approximately 10-30 different products. However, we carry the largest line of products that we know of including over 100 products. As of March 31, 2020, Global Wholehealth Partners Corp. has made no sales.

 

 15 
 

Marketing and Sales

 

The company plans on selling through large and small distributors, giving the company the greatest opportunity to sell to a greater amount of people, doctors, hospitals, clinics and governments.

 

Research and Development:

 

We are continuing to look for needs in the world to create and work with our scientific team and science partners to make a rapid test for the newest diseases, such as ZIKA, EBOLA, TB, and Malaria.

  

Results of Operations

 

Three and nine months ended March 31, 2020 compared with the three and nine months ended March 31, 2019

 

Operating Expenses

 

A summary of our operating expense for the three months ended March 31, 2020 compared with the three months ended March 31, 2019 follows:

 

    

Three Months Ended

March 31,

    

Three Months Ended

March 31,

    Increase/ 
    2020    2019    (Decrease) 
Operating expenses:               
   Professional fees  $9,000   $6,738   $2,262 
   Research and development   443,750    —      443,750 
   Selling, general and administrative   2,629    2,270    359 
Total operating expenses  $455,379   $9,008   $446,371 

 

A summary of our operating expense for the nine months ended March 31, 2020 compared with the nine months ended March 31, 2019 follows:

 

    

Nine Months Ended

March 31,

    

Nine Months Ended

March 31,

    Increase/ 
    2020    2019    (Decrease) 
Operating expenses:               
   Professional fees  $44,900   $6,738   $38,162 
   Research and development   443,750    —      443,750 
   Selling, general and administrative   36,625    2,810    33,755 
Total operating expenses  $525,275   $9,608   $515,667 

 

Professional Fees

 

Professional fees relate to expenditures incurred primarily for legal and accounting services. During the three and nine months ended March 31, 2020 compared to the three and nine months ended March 31, 2019, professional fees increased $2,262 and $38,162, respectively. The increase was due to increased professional and management fees incurred in furtherance of the Company’s business plan and the administration of the public entity.

 

 16 
 

Research and Product Development

 

Research and Product Development (“R&D”) costs represent costs incurred to develop our tests and are incurred pursuant to agreements with other third-party providers and certain internal R&D cost allocations when applicable. R&D costs are expensed when incurred. During the three and nine months ended March 31, 2020 compared to the three and nine months ended March 31, 2019, R&D costs increased as a result of a $443,750 increase related to testing and development of the Company’s Co Vid-19 rapid test.

 

Selling, General and Administrative

 

Selling, general and administrative (“SG&A”) costs include all expenditures related to personnel, travel and entertainment, public company compliance costs, insurance and other office related costs. During the three and nine months ended March 31, 2020 compared to the three and nine months ended March 31, 2019, SG&A increased $359 and $33,755, respectively. The increase was due to increased cost incurred in furtherance of the Company’s business plan and the administration of the public entity.

 

Other Income

 

Other income increased $443,750 as a result of the forgiveness of debt incurred related to the Company’s CoVid-19 test costs, please see Note 4 and Note 5 to the Company’s Consolidated Financial Statements for additional information.

 

Liquidity and Capital Resources

 

As of March 31, 2020, our assets consisted of $668 in cash and $23,372 in inventory compared to current liabilities of $65,747. From inception to March 31, 2020, we have incurred an accumulated deficit of $544,607. This loss has been incurred through a combination of professional fees, R&D and SG&A costs to support our plans to develop our business. During the nine months ended March 31, 2020 and 2019, the Company had no revenue and incurred a loss from operations of $525,275 and $9,608, respectively. The Company has incurred losses since inception and may not be able to generate sufficient net revenue from its business in the future to achieve or sustain profitability. The Company currently has insufficient funds to operate over the next twelve months. To finance our operations, we are currently pursuing additional funds through equity or debt financing or a combination thereof. The Company currently has no commitments to obtain any such financing, and there can be no assurance that financing will be available in amounts or on terms acceptable to the Company, if at all.

 

Summary of Cash Flows

 

Presented below is a table that summarizes the cash provided or used in our activities and the amount of the respective increases or decreases in cash provided by (used in) those activities between the fiscal periods:

 

   Nine Months Ended March 31,  Increase/
   2020  2019  Decrease
Operating activities  $(102,125)  $—     $102,125 
Investing activities   —      —      —   
Financing activities   82,875    —      82,875 
Net increase (decrease) in cash and cash equivalents  $(19,250)  $—     $185,000 

 

Operating Activities

 

Net cash used in operating activities increased $102,125 due to increases in professional fees and SG&A costs.

 

Investing Activities

 

The Company had no investing activities during the three and nine months ended March 31, 2020 or 2019.

 17 
 

Financing Activities

 

During the nine months ended March 31, 2020, the Company received $20,000 upon the sale of 2,000,000 shares of common stock to LionsGate for $0.01 per share and net related party advances totaling $62,875.

 

Other Contractual Obligations

 

None.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 

Recently Issued Accounting Pronouncements

 

See Note 2 to our Financial Statements for more information regarding recent accounting pronouncements and their impact to our results of operations and financial position.

 

New Accounting Standards to be Adopted Subsequent to March 31, 2020

 

None.

 

Critical Accounting Policies and Significant Judgments’ and Use of Estimates

 

We have prepared our consolidated financial statements in conformity with accounting principles generally accepted in the United States. Our preparation of these financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. These estimates can also affect supplemental disclosures including information about contingencies, risk and financial condition. Critical accounting estimates are defined as those that are reflective of significant judgments and uncertainties and potentially yield materially different results under different assumptions or conditions. Given current facts and circumstances, we believe that our estimates and assumptions are reasonable, adhere to GAAP and are consistently applied. We evaluate our estimates and judgments on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions. Our critical accounting policies are more fully described above under the Notes to Financial Statements “NOTE 2 – Summary of Significant Accounting Policies”.

 

Related Party Transactions

 

For a discussion of our Related Party Transactions, refer to “Note 4 - Related Party Transactions” to our Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this quarterly report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that as of March 31, 2020, that our disclosure controls and procedures were effective such that the information required to be disclosed in our SEC filings is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

 18 
 

Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

PART II – OTHER INFORMATION

 

Item 1A. Risk Factors

 

Co Vid-19 Pandemic Impact and Risk

 

At this time, it is not possible to fully assess the impact of the Co Vid-19 pandemic on the Company’s operations and capital requirements. Should the Co Vid-19 pandemic continue, it may adversely affect the Company’s ability to (i) retain employees and consultants; (ii) obtain additional financing on terms acceptable to the Company, if at all; (iii) delay regulatory submissions and approvals; (iv) delay, limit or preclude the Company from securing manufacturing sites or partnerships; (v) delay, limit or preclude the Company from achieving technology or product development goals, milestones, or objectives; and (vi) preclude or delay entry into joint venture or partnership arrangements. The occurrence of any one or more of such events may affect the Company’s ability to execute on its business plan.

 

The Company’s priority and commitment is to the health and security of its team members, their families and its partners through this unprecedented event.

 

Item 5. Other information

 

On January 1, 2020, in addition to the position of CEO, the Board of Directors appointed Charles Strongo to the position of Secretary commensurate with the resignation of Sara Gonzales. The resignation by Ms. Gonzales was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 19 
 

Item 6. Exhibits

 

Exhibit No. Description of Exhibit
10.1

Form of Promissory Note between LionsGate Funding Group LLC and Global WholeHealth Partners Corp. dated March 29, 2020.*

99.1 Acknowledgement Letter from the FDA dated March 15, 2020*
99.2

Acknowledgement Letter from the FDA dated April 6, 2020 (Incorporated by reference to the Form 8-K filed on April 10, 2020)

31.1 Certification of Principal Executive Officer Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2 Certification of Principal Financial Officer Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1 Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
101.INS XBRL Instance Document**
101.SCH XBRL Taxonomy Extension Schema Document**
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document**
101.DEF XBRL Taxonomy Extension Definition Linkbase Document**
101.LAB XBRL Taxonomy Extension Label Linkbase Document**
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document**

 

____________________

 

*Filed herewith

 

** Furnished herewith. XBRL (eXtensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

 20 
 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Global WholeHealth Partners Corp.

 

By: /S/ Charles Strongo

Charles Strongo

Chief Executive Officer and Director

(Principal Executive Officer)

 

Date: May 7, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 21 

 EX-10 2 ex10.htm FORM OF PROMISSORY NOTE BETWEEN LIONSGATE FUNDING GROUP LLC AND GLOBAL WHOLEHEALTH PARTNERS CORP. DATED MARCH 29, 2020.

 

 

 EX-31 3 ex311.htm CERTIFICATION PURSUANT TO RULE 13A-14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

Exhibit 31.1

 

CERTIFICATION PURSUANT TO RULE 13A-14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Charles Strongo, certify that:

 

1.        I have reviewed this quarterly report on Form 10-Q of Global WholeHealth Partners Corp. (the “Registrant”);

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.As the registrant’s certifying officer I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant is made known to me by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.As the registrant's certifying officer I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 7, 2020

/s/ Charles Strongo

Charles Strongo

Chief Executive Officer and Director

(Principal Executive Officer)

  

 

 EX-31 4 ex312.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13A-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 31.2

 

CERTIFICATION PURSUANT TO RULE 13A-14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Richard Johnson, certify that:

 

1.       I have reviewed this quarterly report on Form 10-Q of Global WholeHealth Partners Corp (the “Registrant”);

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.As the registrant’s certifying officer I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant is made known to me by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.As the registrant's certifying officer I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 7, 2020

 

/s/ Richard Johnson

Richard Johnson

Chief Financial Officer and Director

(Principal Financial Officer)

  

 

 EX-32 5 ex32.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

The undersigned, as the Chief Executive Officer and the Chief Financial Officer of Global WholeHealth Partners Corp., respectively, certifies that, to the best of their knowledge and belief, the Quarterly Report on Form 10-Q for the three and nine months ended March 31, 2020 that accompanies this certification fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of Global WholeHealth Partners Corp. at the dates and for the periods indicated. The foregoing certification is made pursuant to 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) and shall not be relied upon for any other purpose.

 

Date: May 7, 2020

/s/ Charles Strongo

Charles Strongo

Chief Executive Officer and Director

(Principal Executive Officer)

 

Date: May 7, 2020

 

/s/ Richard Johnson

Richard Johnson

Chief Financial Officer and Director

(Principal Financial Officer)

 

  

 

 EX-99 6 ex991.htm ACKNOWLEDGEMENT LETTER FROM THE FDA DATED MARCH 15, 2020

 

 GRAPHIC 7 ex10.jpg GRAPHIC begin 644 ex10.jpg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ex99.jpg GRAPHIC begin 644 ex99.jpg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gwhp-20200331.xml XBRL INSTANCE FILE 0001598308 2019-07-01 2020-03-31 0001598308 2020-05-07 0001598308 2019-06-30 0001598308 2020-01-01 2020-03-31 0001598308 2019-01-01 2019-03-31 0001598308 2018-07-01 2019-03-31 0001598308 2020-03-31 0001598308 2018-06-30 0001598308 2018-12-31 0001598308 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001598308 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001598308 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0001598308 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0001598308 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001598308 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001598308 us-gaap:CommonStockMember 2019-06-30 0001598308 us-gaap:CommonStockMember 2019-09-30 0001598308 us-gaap:CommonStockMember 2018-06-30 0001598308 us-gaap:CommonStockMember 2018-09-30 0001598308 us-gaap:CommonStockMember 2019-12-31 0001598308 us-gaap:CommonStockMember 2018-12-31 0001598308 us-gaap:CommonStockMember 2020-03-31 0001598308 us-gaap:CommonStockMember 2019-03-31 0001598308 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001598308 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001598308 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0001598308 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0001598308 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001598308 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001598308 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001598308 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001598308 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001598308 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001598308 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001598308 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001598308 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001598308 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001598308 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001598308 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001598308 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0001598308 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0001598308 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001598308 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001598308 us-gaap:RetainedEarningsMember 2019-06-30 0001598308 us-gaap:RetainedEarningsMember 2019-09-30 0001598308 us-gaap:RetainedEarningsMember 2018-06-30 0001598308 us-gaap:RetainedEarningsMember 2018-09-30 0001598308 us-gaap:RetainedEarningsMember 2019-12-31 0001598308 us-gaap:RetainedEarningsMember 2018-12-31 0001598308 us-gaap:RetainedEarningsMember 2020-03-31 0001598308 us-gaap:RetainedEarningsMember 2019-03-31 0001598308 2019-07-01 2019-09-30 0001598308 2018-07-01 2018-09-30 0001598308 2019-10-01 2019-12-31 0001598308 2018-10-01 2018-12-31 0001598308 2019-09-30 0001598308 2018-09-30 0001598308 2019-12-31 0001598308 2019-03-31 0001598308 us-gaap:CommonStockMember 2019-05-08 2019-05-09 0001598308 us-gaap:CommonStockMember us-gaap:MajorityShareholderMember 2019-05-22 2019-05-23 0001598308 us-gaap:MajorityShareholderMember us-gaap:CommonStockMember 2019-07-01 2020-03-31 0001598308 us-gaap:MajorityShareholderMember 2019-03-31 0001598308 us-gaap:MajorityShareholderMember 2020-01-01 2020-03-31 0001598308 us-gaap:MajorityShareholderMember 2019-07-01 2020-03-31 0001598308 GWHP:ChiefScienceOfficerMember 2020-01-01 2020-03-31 0001598308 us-gaap:MajorityShareholderMember us-gaap:NotesPayableOtherPayablesMember 2020-03-29 0001598308 us-gaap:MajorityShareholderMember us-gaap:NotesPayableOtherPayablesMember 2020-03-28 2020-03-30 0001598308 us-gaap:MajorityShareholderMember us-gaap:NotesPayableOtherPayablesMember 2020-01-01 2020-03-31 0001598308 us-gaap:MajorityShareholderMember us-gaap:NotesPayableOtherPayablesMember 2019-10-01 2020-03-31 0001598308 us-gaap:MajorityShareholderMember us-gaap:NotesPayableOtherPayablesMember 2020-03-30 0001598308 us-gaap:MajorityShareholderMember us-gaap:NotesPayableOtherPayablesMember 2020-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 10-Q false 2020-03-31 Q3 2020 --06-30 Global Wholehealth Partners Corp 0001598308 Yes Non-accelerated Filer true false 58116358 true 000-56035 46-2316220 NV 2227 Avenida Oliva San Clemente, California California NV 92673 (714) Yes 19918 24040 19918 24040 23372 19918 668 100 65747 100 65747 100 1372 19918 24040 -463082 -544607 426784 444784 56116 58116 392-9752 false 62875 1500 19818 -41707 -1415 -2015 56116 56116 52 52 58116 52 58116 52 426784 426784 430748 430748 444784 430748 444784 430748 -463082 -481880 -432215 -432515 -532978 -432815 -544607 -441823 1020 -1715 -30078 -11023 0.001 0.001 10000000 10000000 0 0 0 0 0.001 0.001 400000000 400000000 56116358 58116358 56116358 58116358 56116358 56116358 52358 52358 58116358 52358 58116358 52358 -525275 -455379 -9008 -9608 525275 455379 9008 9608 36625 2629 2270 2870 443750 443750 443750 443750 443750 44900 9000 6738 6738 11100 46000 -81525 -11629 -9008 -9608 -18798 -300 -51098 -300 -11629 -9008 -18798 -300 -51098 -300 -0.00 -0.00 -0.17 -0.18 57343755 58116358 52358 52358 2000000 2000000 2000 18000 20000 20000 0.01 0.01 -102125 1272 -1315 1500 10923 23372 82875 62875 455950 506625 20000 -19250 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 1 &#8211; Basis of Presentation, Organization and Going Concern</u></b></p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis of Presentation </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited interim condensed consolidated financial statements of Global WholeHealth Partners Corporation and Subsidiary (the &#8220;Company&#8221;) as of March 31, 2020, and for the three and nine months ended March 31, 2020 and 2019, include the accounts of the Company and its wholly-owned and controlled subsidiary, Global WholeHealth Partners Corp, a private Wyoming corporation, and have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;US GAAP&#8221;), for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results may differ from those estimates. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10 for the year ended&#160;June 30, 2019.In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) necessary for the fair presentation of the Company&#8217;s financial position as of December 31, 2019, results of operations for the three and nine months ended March 31, 2020 and 2019, and stockholders&#8217; equity and cash flows for the three and nine months ended March 31, 2020 and 2019. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.</p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Organization</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Global WholeHealth Partners Corporation was incorporated on March 7, 2013 in the State of Nevada under the name Texas Jack Oil and Gas Corp. On May 9, 2019, the Company amended its Articles of Incorporation to effect a change of name to Global WholeHealth Partners Corporation to align the company name with its focus on health care related development and products. The Company&#8217;s ticker symbol changed to GWHP.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company was originally organized for the purpose of exploration of Oil and Gas. However, the Company was unable to establish an oil and gas concern and was abandoned in 2016. On February 27, 2019, the Clark County District Court of Nevada appointed Barbara Bauman as custodian to the Company. The custodian reestablished the Company in good standing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 9, 2019, the Board reverse split (1-for-500) the outstanding Common Shares of 58,172,000 to 116,358 shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">May 23, 2019, the Company and LionsGate Funding Group LLC (&#8220;LionsGate&#8221;), owner of a majority of the Company&#8217;s outstanding common stock as of May 23, 2019, entered into a Stock Sale and Purchase Agreement (the &#8220;SPA&#8221;) which closed on June 27, 2019. Pursuant the SPA, the Company issued 56,000,000 shares of common stock to LionsGate in exchange for 100% of their interests in Global WholeHealth Partners Corp., a private Wyoming corporation incorporated on April 9, 2019 (&#8220;Global Private&#8221;). Global Private has contacts with suppliers and contract manufacturers in the In vitro diagnostic industry, with rights to sell rapid diagnostic tests, such as the following 6 minute rapid whole blood Ebola Test, 6 minute whole blood Zika test, 8 minute whole blood rapid TB test and 75 plus other tests more than 40 which are FDA approved. Due to the common control of the Company and Global Private, pursuant to ASC 805-50-25, &#8220;Transactions Between Entities Under Common Control&#8221;, the SPA was accounted for as a transfer of the carrying amounts of assets and liabilities under the predecessor value method of accounting. Financial statement presentation under the predecessor values method of accounting as a result of a business combination between entities under common control requires the receiving entity (i.e., the Company) to report the results of operations as if both entities had been combined as of the beginning of the periods presented. The consolidated financial statements include both entities&#8217; full results since the inception of Global Private.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going Concern</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs to allow it to continue as a going concern. As of March 31, 2020, the Company had an accumulated deficit of $544,607. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In view of these conditions, the ability of the Company to continue as a going concern is in doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. Historically, the Company has relied upon internally generated funds, and funds from the sale of stock, issuance of promissory notes and loans from its shareholders and private investors to finance its operations and growth. Management is planning to raise necessary additional funds for working capital through loans and/or additional sales of its common stock. However, there is no assurance that the Company will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should the Company be unable to raise this amount of capital its operating plans will be limited to the amount of capital that it can access. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements.</p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 2 &#8211; Summary of Significant Accounting Policies</u></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Principles of Consolidation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Global WholeHealth Partners Corp, a private Wyoming corporation was incorporated on April 9, 2019 to receive private investor funds and aggregate certain in vitro diagnostic assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements presented are those of Global WholeHealth Partners Corporation and its wholly owned subsidiary, Global Private. All significant intercompany balances and transactions have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Accounting estimates</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Actual results could differ significantly from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cash and cash equivalents</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid instruments purchased with an original maturity of three months or less and money market accounts to be cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Income Taxes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value Measurements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilizes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify">During the periods covered by this report, the Company did not have any assets or liabilities that were required to be measured at fair value on a recurring basis or on a non-recurring basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s financial instruments consist of cash, accounts payable and accrued expenses. The carrying amounts of the Company&#8217;s financial instruments approximate fair value because of the short term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect those estimates. We do not hold or issue financial instruments for trading purposes, nor do we utilize derivative instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Net Income (Loss) Per Share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The computation of basic earnings per share (&#8220;EPS&#8221;) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common shares that would be issued assuming the exercise of all potentially dilutive common shares outstanding using the treasury stock method. The Company had no potentially dilutive securities as of December 31, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>New Accounting Pronouncements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We review new accounting standards as issued. Although some of these accounting standards issued or effective after the end of our previous fiscal year may be applicable to us, we have not identified any standards that we believe merit discussion. We believe that none of the new standards will have a significant impact on our consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 3 &#8211; Stockholder&#8217;s Equity</u></b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Preferred Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has Preferred stock: $0.001 par value; 10,000,000 shares authorized with no shares issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Common Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has 400,000,000 shares of Common Stock authorized of which 58,116,358 and 56,116,358 shares were issued and outstanding as of March 31, 2020 and June 30, 2019, respectively. During the nine months ended March 31, 2020, the number of shares increased by 2,000,000 as a result of the Company selling 2,000,000 shares at $0.01 per share to LionsGate in exchange for cash of $20,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 4 &#8211; Related Party Transactions</u></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended March 31, 2020, the Company received $20,000 upon the sale of 2,000,000 shares of common stock to LionsGate for $0.01 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time-to-time the Company receives shareholder advances to cover operating costs which are reflected on the balance sheet as related party advances. During the three months ended March 31, 2020, LionsGate provided advances totaling $455,950 which was used to pay professional fees of $11,100, research studies for the development of its CoVid-19 tests of $443,750 and general costs of $1,100. During the nine months ended March 31, 2020, LionsGate provided advances totaling $506,625 which was used to pay professional fees of $46,000, research studies for the development of CoVid-19 tests of $443,750 and general costs of $16,875.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2020, the Company paid $431,250 to Pan Probe Biotech to perform studies in validation of the Company&#8217;s CoVid-19 tests. Dr. Shujie Cui is the Company&#8217;s Chief Science Officer and 100% owner of Pan Probe.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 6 &#8211; Subsequent Events</u></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has reviewed material events subsequent of the period ended March 31, 2020 and prior to the filing of our consolidated financial statements in accordance with FASB ASC 855 &#8220;Subsequent Events&#8221;.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The recent outbreak of the novel coronavirus CoVid-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies and created uncertainty regarding potential impacts to the Company&#8217;s employees and R&#38;D activities. The CoVid-19 pandemic has impacted and could further impact the Company&#8217;s operations and the operations of the Company&#8217;s vendors as a result of quarantines, facility closures, and travel and logistics restrictions. The extent to which the CoVid-19 pandemic impacts the Company&#8217;s business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to the duration, spread, severity, and impact of the CoVid-19 pandemic, the effects of the CoVid-19 pandemic on the Company&#8217;s customers, suppliers, and vendors and the remedial actions and stimulus measures adopted by local, state and federal governments, and to what extent normal economic and operating conditions can resume. Even after the CoVid-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Therefore, the Company cannot reasonably estimate the impact at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis of Presentation </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited interim condensed consolidated financial statements of Global WholeHealth Partners Corporation and Subsidiary (the &#8220;Company&#8221;) as of March 31, 2020, and for the three and nine months ended March 31, 2020 and 2019, include the accounts of the Company and its wholly-owned and controlled subsidiary, Global WholeHealth Partners Corp, a private Wyoming corporation, and have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;US GAAP&#8221;), for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results may differ from those estimates. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10 for the year ended&#160;June 30, 2019.In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) necessary for the fair presentation of the Company&#8217;s financial position as of December 31, 2019, results of operations for the three and nine months ended March 31, 2020 and 2019, and stockholders&#8217; equity and cash flows for the three and nine months ended March 31, 2020 and 2019. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.</p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Organization</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Global WholeHealth Partners Corporation was incorporated on March 7, 2013 in the State of Nevada under the name Texas Jack Oil and Gas Corp. On May 9, 2019, the Company amended its Articles of Incorporation to effect a change of name to Global WholeHealth Partners Corporation to align the company name with its focus on health care related development and products. The Company&#8217;s ticker symbol changed to GWHP.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company was originally organized for the purpose of exploration of Oil and Gas. However, the Company was unable to establish an oil and gas concern and was abandoned in 2016. On February 27, 2019, the Clark County District Court of Nevada appointed Barbara Bauman as custodian to the Company. The custodian reestablished the Company in good standing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 9, 2019, the Board reverse split (1-for-500) the outstanding Common Shares of 58,172,000 to 116,358 shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">May 23, 2019, the Company and LionsGate Funding Group LLC (&#8220;LionsGate&#8221;), owner of a majority of the Company&#8217;s outstanding common stock as of May 23, 2019, entered into a Stock Sale and Purchase Agreement (the &#8220;SPA&#8221;) which closed on June 27, 2019. Pursuant the SPA, the Company issued 56,000,000 shares of common stock to LionsGate in exchange for 100% of their interests in Global WholeHealth Partners Corp., a private Wyoming corporation incorporated on April 9, 2019 (&#8220;Global Private&#8221;). Global Private has contacts with suppliers and contract manufacturers in the In vitro diagnostic industry, with rights to sell rapid diagnostic tests, such as the following 6 minute rapid whole blood Ebola Test, 6 minute whole blood Zika test, 8 minute whole blood rapid TB test and 75 plus other tests more than 40 which are FDA approved. Due to the common control of the Company and Global Private, pursuant to ASC 805-50-25, &#8220;Transactions Between Entities Under Common Control&#8221;, the SPA was accounted for as a transfer of the carrying amounts of assets and liabilities under the predecessor value method of accounting. Financial statement presentation under the predecessor values method of accounting as a result of a business combination between entities under common control requires the receiving entity (i.e., the Company) to report the results of operations as if both entities had been combined as of the beginning of the periods presented. The consolidated financial statements include both entities&#8217; full results since the inception of Global Private.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going Concern</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs to allow it to continue as a going concern. As of March 31, 2020, the Company had an accumulated deficit of $544,607. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In view of these conditions, the ability of the Company to continue as a going concern is in doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. Historically, the Company has relied upon internally generated funds, and funds from the sale of stock, issuance of promissory notes and loans from its shareholders and private investors to finance its operations and growth. Management is planning to raise necessary additional funds for working capital through loans and/or additional sales of its common stock. However, there is no assurance that the Company will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should the Company be unable to raise this amount of capital its operating plans will be limited to the amount of capital that it can access. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements.</p> 1-for-500 58172000 116358 The Company issued 56,000,000 shares of common stock to LionsGate in exchange for 100% of their interests in Global WholeHealth Partners Corp 1100 16875 During the three months ended March 31, 2020, the Company paid $431,250 to Pan Probe Biotech to perform studies in validation of the Company’s COVID-19 tests. Dr. Shujie Cui is the Company’s Chief Science Officer and 100% owner of Pan Probe 443750 443750 2020-06-30 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Principles of Consolidation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Global WholeHealth Partners Corp, a private Wyoming corporation was incorporated on April 9, 2019 to receive private investor funds and aggregate certain in vitro diagnostic assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements presented are those of Global WholeHealth Partners Corporation and its wholly owned subsidiary, Global Private. All significant intercompany balances and transactions have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Accounting estimates</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Actual results could differ significantly from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cash and cash equivalents</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid instruments purchased with an original maturity of three months or less and money market accounts to be cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Income Taxes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value Measurements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilizes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify">During the periods covered by this report, the Company did not have any assets or liabilities that were required to be measured at fair value on a recurring basis or on a non-recurring basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s financial instruments consist of cash, accounts payable and accrued expenses. The carrying amounts of the Company&#8217;s financial instruments approximate fair value because of the short term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect those estimates. We do not hold or issue financial instruments for trading purposes, nor do we utilize derivative instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Net Income (Loss) Per Share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The computation of basic earnings per share (&#8220;EPS&#8221;) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common shares that would be issued assuming the exercise of all potentially dilutive common shares outstanding using the treasury stock method. The Company had no potentially dilutive securities as of December 31, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>New Accounting Pronouncements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We review new accounting standards as issued. Although some of these accounting standards issued or effective after the end of our previous fiscal year may be applicable to us, we have not identified any standards that we believe merit discussion. We believe that none of the new standards will have a significant impact on our consolidated financial statements.</p> 443750 443750 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 5 &#8211; Promissory Note</u></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 29, 2020, the Company issued a Promissory Note (the &#8220;<b>Note</b>&#8221;) to LionsGate in the amount of $506,625 which was equivalent to the advances made to the Company up to March 29, 2020. On March 30, 2020, LG decided it would be in the best interests of the Company to forgive the portion of the Note related to testing costs which totaled $443,750. As a result, the Company recognized $443,750 of other income for the three and six months ended March 31, 2020 leaving a Note balance of $62,875. The terms of the Note provide total funding of up to $585,000 or an additional $78,375. The Note bears interest at the rate of 5% per annum and the principal and interest is due and payable in full in 90 days on June 30, 2020. If not paid within the 90 days a 5% penalty will be added to the Note and the term will extend for an additional 90 days.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Note was issued by the Company under the exemption from registration afforded by Section 4(a)(2) of the Securities Act, as amended and/or Regulation D promulgated thereunder, as the securities were issued to accredited investors, without a view to distribution, and were not issued through any general solicitation or advertisement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> 431250 506625 0.05 585000 62875 78375 The Note bears interest at the rate of 5% per annum and the principal and interest is due and payable in full in 90 days on June 30, 2020. If not paid within the 90 days a 5% penalty will be added to the Note and the term will extend for an additional 90 days. EX-101.SCH 10 gwhp-20200331.xsd XBRL SCHEMA FILE 00000001 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements Of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements Of Stockholders Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements Of Stockholders Deficit (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements Of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Basis Of Presentation, Organization And Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary Of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Stockholder's Equity link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Promissory Note link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Basis of Presentation, Organization And Going Concern (Policies) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Summary Of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Organization (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Related Party Transactions (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Promissory Note (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 gwhp-20200331_cal.xml XBRL CALCULATION FILE EX-101.DEF 12 gwhp-20200331_def.xml XBRL DEFINITION FILE EX-101.LAB 13 gwhp-20200331_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Deficit [Member] Related Party [Axis] LionsGate Funding Group LLC [Member] Dr. Shujie Cui Is The Company's Chief Science Officer And Owner Of Pan Probe Biotech [Member] Short-term Debt, Type [Axis] Promissory Note [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash Inventory Total current assets Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Related party note Related party advances Accounts payable and accrued liabilities Total current liabilities Total liabilities Commitments and contingencies Stockholders' equity (deficit): Preferred stock; $0.001 par value, 10,000,000 shares authorized, no shares issued or outstanding at March 31, 2020 and June 30, 2019, respectively Common stock; $0.001 par value, 400,000,000 shares authorized, 58,116,358 and 56,116,358 shares issued and outstanding at March 31, 2020 and June 30, 2019, respectively Additional paid-in capital Retained deficit Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, par value per share Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value per share Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expense Professional fees Research and development Selling, general and administrative Total operating expense Loss from operations Other income Gain on forgiveness of liabilities Net loss Basic and Diluted Loss per Common Share Weighted average number of common shares outstanding - basic and diluted Statement [Table] Statement [Line Items] Balance, common shares Balance, amount Common stock issued to related party for cash at $0.01 per share, shares Common stock issued to related party for cash at $0.01 per share, amount Net loss Balance, common shares Balance, amount Statement of Stockholders' Equity [Abstract] Stock issued to related party price per share Statement of Cash Flows [Abstract] Cash flows from operating activities Adjustments to reconcile net loss to net cash flows used in operating activities: Common stock issued for services Common stock issued for debt settlement Changes in operating assets and liabilities: (Increase) decrease in inventory Increase (decrease) in related party advances Increase (decrease) in accounts payable and accrued expenses Net cash flows from operating activities Cash flows from financing activities Cash for common shares of stock Proceeds from related party note, net Net cash flows from financing activities Change in cash Cash at beginning of period Cash at end of period Supplemental disclosure of cash flow information: Interest paid in cash Income taxes paid in cash Basis Of Presentation Organization And Going Concern Basis of Presentation, Organization and Going Concern Summary Of Significant Accounting Policies Summary of Significant Accounting Policies Stockholders Equity Stockholder’s Equity Related Party Transactions Related Party Transactions Promissory Note Promissory Note Subsequent Events Subsequent Events Basis Of Presentation Organization And Going Concern Basis of Presentation Organization Going Concern Summary Of Significant Accounting Policies Principles of Consolidation Accounting estimates Cash and cash equivalents Income Taxes Fair Value Measurements Fair Value of Financial Instruments Net Income (Loss) Per Share New Accounting Pronouncements Reverse stock split Reverse stock split outstanding common stock Reverse stock split during the period Exchange of common stock shares to Lion gate Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Common stock issued to related party, shares Common stock issued to related party, amount Advances from related party Research studies for development of Co Vid -19 tests General costs Paid to Pan Probe Biotech to perform studies Related Party Description Schedule of Short-term Debt [Table] Short-term Debt [Line Items] Debt instrument face amount Research and development expenses Other Income Debt instrument carrying amount Proceeds from issuance of notes payable Additional issuance of notes payable Promissory note interest rate Promissory notes description Promissory notes maturity date Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Related Party Transactions Disclosure [Text Block] Short-term Debt [Text Block] Subsequent Events [Text Block] EX-101.PRE 14 gwhp-20200331_pre.xml XBRL PRESENTATION FILE XML 15 R17.htm IDEA: XBRL DOCUMENT v3.20.1
Related Party Transactions (Narrative) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Related Party Transaction [Line Items]          
Common stock issued to related party, amount   $ 20,000      
Stock issued to related party price per share $ 0.01     $ 0.01  
Advances from related party       $ 62,875
Professional fees $ 9,000   $ 6,738 44,900 6,738
Research studies for development of Co Vid -19 tests 443,750   443,750
Common Stock [Member]          
Related Party Transaction [Line Items]          
Common stock issued to related party, shares   2,000,000      
Common stock issued to related party, amount   $ 2,000      
LionsGate Funding Group LLC [Member]          
Related Party Transaction [Line Items]          
Stock issued to related party price per share     $ 0.01   $ 0.01
Advances from related party 455,950     506,625  
Professional fees 11,100     46,000  
Research studies for development of Co Vid -19 tests 443,750     443,750  
General costs 1,100     $ 16,875  
LionsGate Funding Group LLC [Member] | Common Stock [Member]          
Related Party Transaction [Line Items]          
Common stock issued to related party, shares       2,000,000  
Common stock issued to related party, amount       $ 20,000  
Dr. Shujie Cui Is The Company's Chief Science Officer And Owner Of Pan Probe Biotech [Member]          
Related Party Transaction [Line Items]          
Paid to Pan Probe Biotech to perform studies $ 431,250        
Related Party Description During the three months ended March 31, 2020, the Company paid $431,250 to Pan Probe Biotech to perform studies in validation of the Company’s COVID-19 tests. Dr. Shujie Cui is the Company’s Chief Science Officer and 100% owner of Pan Probe        

XML 16 R13.htm IDEA: XBRL DOCUMENT v3.20.1
Subsequent Events
 9 Months Ended
Mar. 31, 2020
Subsequent Events  
Subsequent Events

NOTE 6 – Subsequent Events

 

Management has reviewed material events subsequent of the period ended March 31, 2020 and prior to the filing of our consolidated financial statements in accordance with FASB ASC 855 “Subsequent Events”.

 

The recent outbreak of the novel coronavirus CoVid-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies and created uncertainty regarding potential impacts to the Company’s employees and R&D activities. The CoVid-19 pandemic has impacted and could further impact the Company’s operations and the operations of the Company’s vendors as a result of quarantines, facility closures, and travel and logistics restrictions. The extent to which the CoVid-19 pandemic impacts the Company’s business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to the duration, spread, severity, and impact of the CoVid-19 pandemic, the effects of the CoVid-19 pandemic on the Company’s customers, suppliers, and vendors and the remedial actions and stimulus measures adopted by local, state and federal governments, and to what extent normal economic and operating conditions can resume. Even after the CoVid-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Therefore, the Company cannot reasonably estimate the impact at this time.

 
EXCEL 17 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 18 R3.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2020
Jun. 30, 2019
Statement of Financial Position [Abstract]    
Preferred stock, par value per share $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value per share $ 0.001 $ 0.001
Common stock, shares authorized 400,000,000 400,000,000
Common stock, shares issued 58,116,358 56,116,358
Common stock, shares outstanding 58,116,358 56,116,358
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements Of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Cash flows from operating activities    
Net loss $ (81,525) $ (9,608)
Adjustments to reconcile net loss to net cash flows used in operating activities:    
Common stock issued for services
Common stock issued for debt settlement
Changes in operating assets and liabilities:    
(Increase) decrease in inventory 23,372
Increase (decrease) in related party advances 1,500 10,923
Increase (decrease) in accounts payable and accrued expenses 1,272 (1,315)
Net cash flows from operating activities (102,125)
Cash flows from financing activities    
Cash for common shares of stock 20,000
Proceeds from related party note, net 62,875
Net cash flows from financing activities 82,875
Change in cash (19,250)
Cash at beginning of period 19,918
Cash at end of period 668
Supplemental disclosure of cash flow information:    
Interest paid in cash
Income taxes paid in cash
XML 20 R2.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Balance Sheets - USD ($)
Mar. 31, 2020
Jun. 30, 2019
Current assets:    
Cash $ 668 $ 19,918
Inventory 23,372
Total current assets 24,040 19,918
Total assets 24,040 19,918
Current liabilities:    
Related party note 62,875
Related party advances 1,500
Accounts payable and accrued liabilities 1,372 100
Total current liabilities 65,747 100
Total liabilities 65,747 100
Stockholders' equity (deficit):    
Preferred stock; $0.001 par value, 10,000,000 shares authorized, no shares issued or outstanding at March 31, 2020 and June 30, 2019, respectively
Common stock; $0.001 par value, 400,000,000 shares authorized, 58,116,358 and 56,116,358 shares issued and outstanding at March 31, 2020 and June 30, 2019, respectively 58,116 56,116
Additional paid-in capital 444,784 426,784
Retained deficit (544,607) (463,082)
Total stockholders' equity (41,707) 19,818
Total liabilities and stockholders' equity $ 24,040 $ 19,918
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements Of Stockholders Deficit (Unaudited) (Parenthetical)
Mar. 31, 2020
$ / shares
Statement of Stockholders' Equity [Abstract]  
Stock issued to related party price per share $ 0.01
XML 22 R16.htm IDEA: XBRL DOCUMENT v3.20.1
Organization (Narrative) (Details) - Common Stock [Member] - shares
May 23, 2019
May 09, 2019
Reverse stock split   1-for-500
Reverse stock split outstanding common stock   58,172,000
Reverse stock split during the period   116,358
LionsGate Funding Group LLC [Member]    
Exchange of common stock shares to Lion gate The Company issued 56,000,000 shares of common stock to LionsGate in exchange for 100% of their interests in Global WholeHealth Partners Corp  
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.20.1
Promissory Note
 9 Months Ended
Mar. 31, 2020
Promissory Note  
Promissory Note

NOTE 5 – Promissory Note

 

On March 29, 2020, the Company issued a Promissory Note (the “Note”) to LionsGate in the amount of $506,625 which was equivalent to the advances made to the Company up to March 29, 2020. On March 30, 2020, LG decided it would be in the best interests of the Company to forgive the portion of the Note related to testing costs which totaled $443,750. As a result, the Company recognized $443,750 of other income for the three and six months ended March 31, 2020 leaving a Note balance of $62,875. The terms of the Note provide total funding of up to $585,000 or an additional $78,375. The Note bears interest at the rate of 5% per annum and the principal and interest is due and payable in full in 90 days on June 30, 2020. If not paid within the 90 days a 5% penalty will be added to the Note and the term will extend for an additional 90 days.

 

The Note was issued by the Company under the exemption from registration afforded by Section 4(a)(2) of the Securities Act, as amended and/or Regulation D promulgated thereunder, as the securities were issued to accredited investors, without a view to distribution, and were not issued through any general solicitation or advertisement.

 
XML 25 R8.htm IDEA: XBRL DOCUMENT v3.20.1
Basis Of Presentation, Organization And Going Concern
 9 Months Ended
Mar. 31, 2020
Basis Of Presentation Organization And Going Concern  
Basis of Presentation, Organization and Going Concern

NOTE 1 – Basis of Presentation, Organization and Going Concern

 

Basis of Presentation

 

The accompanying unaudited interim condensed consolidated financial statements of Global WholeHealth Partners Corporation and Subsidiary (the “Company”) as of March 31, 2020, and for the three and nine months ended March 31, 2020 and 2019, include the accounts of the Company and its wholly-owned and controlled subsidiary, Global WholeHealth Partners Corp, a private Wyoming corporation, and have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”), for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted.

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results may differ from those estimates. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10 for the year ended June 30, 2019.In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) necessary for the fair presentation of the Company’s financial position as of December 31, 2019, results of operations for the three and nine months ended March 31, 2020 and 2019, and stockholders’ equity and cash flows for the three and nine months ended March 31, 2020 and 2019. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.

 

Organization

 

Global WholeHealth Partners Corporation was incorporated on March 7, 2013 in the State of Nevada under the name Texas Jack Oil and Gas Corp. On May 9, 2019, the Company amended its Articles of Incorporation to effect a change of name to Global WholeHealth Partners Corporation to align the company name with its focus on health care related development and products. The Company’s ticker symbol changed to GWHP.

 

The Company was originally organized for the purpose of exploration of Oil and Gas. However, the Company was unable to establish an oil and gas concern and was abandoned in 2016. On February 27, 2019, the Clark County District Court of Nevada appointed Barbara Bauman as custodian to the Company. The custodian reestablished the Company in good standing.

 

On May 9, 2019, the Board reverse split (1-for-500) the outstanding Common Shares of 58,172,000 to 116,358 shares.

 

May 23, 2019, the Company and LionsGate Funding Group LLC (“LionsGate”), owner of a majority of the Company’s outstanding common stock as of May 23, 2019, entered into a Stock Sale and Purchase Agreement (the “SPA”) which closed on June 27, 2019. Pursuant the SPA, the Company issued 56,000,000 shares of common stock to LionsGate in exchange for 100% of their interests in Global WholeHealth Partners Corp., a private Wyoming corporation incorporated on April 9, 2019 (“Global Private”). Global Private has contacts with suppliers and contract manufacturers in the In vitro diagnostic industry, with rights to sell rapid diagnostic tests, such as the following 6 minute rapid whole blood Ebola Test, 6 minute whole blood Zika test, 8 minute whole blood rapid TB test and 75 plus other tests more than 40 which are FDA approved. Due to the common control of the Company and Global Private, pursuant to ASC 805-50-25, “Transactions Between Entities Under Common Control”, the SPA was accounted for as a transfer of the carrying amounts of assets and liabilities under the predecessor value method of accounting. Financial statement presentation under the predecessor values method of accounting as a result of a business combination between entities under common control requires the receiving entity (i.e., the Company) to report the results of operations as if both entities had been combined as of the beginning of the periods presented. The consolidated financial statements include both entities’ full results since the inception of Global Private.

  

Going Concern

 

The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs to allow it to continue as a going concern. As of March 31, 2020, the Company had an accumulated deficit of $544,607. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

 

In view of these conditions, the ability of the Company to continue as a going concern is in doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. Historically, the Company has relied upon internally generated funds, and funds from the sale of stock, issuance of promissory notes and loans from its shareholders and private investors to finance its operations and growth. Management is planning to raise necessary additional funds for working capital through loans and/or additional sales of its common stock. However, there is no assurance that the Company will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should the Company be unable to raise this amount of capital its operating plans will be limited to the amount of capital that it can access. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements.
XML 26 R4.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements Of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Income Statement [Abstract]        
Revenue
Operating expense        
Professional fees 9,000 6,738 44,900 6,738
Research and development 443,750 443,750
Selling, general and administrative 2,629 2,270 36,625 2,870
Total operating expense 455,379 9,008 525,275 9,608
Loss from operations (455,379) (9,008) (525,275) (9,608)
Other income        
Gain on forgiveness of liabilities 443,750 443,750
Net loss $ (11,629) $ (9,008) $ (81,525) $ (9,608)
Basic and Diluted Loss per Common Share $ (0.00) $ (0.17) $ (0.00) $ (0.18)
Weighted average number of common shares outstanding - basic and diluted 58,116,358 52,358 57,343,755 52,358
ZIP 27 0001262463-20-000183-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001262463-20-000183-xbrl.zip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�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htm IDEA: XBRL DOCUMENT v3.20.1
Basis of Presentation, Organization And Going Concern (Policies)
 9 Months Ended
Mar. 31, 2020
Disclosure Basis Of Presentation Organization And Going Concern Policies Abstract  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited interim condensed consolidated financial statements of Global WholeHealth Partners Corporation and Subsidiary (the “Company”) as of March 31, 2020, and for the three and nine months ended March 31, 2020 and 2019, include the accounts of the Company and its wholly-owned and controlled subsidiary, Global WholeHealth Partners Corp, a private Wyoming corporation, and have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”), for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted.

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results may differ from those estimates. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10 for the year ended June 30, 2019.In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) necessary for the fair presentation of the Company’s financial position as of December 31, 2019, results of operations for the three and nine months ended March 31, 2020 and 2019, and stockholders’ equity and cash flows for the three and nine months ended March 31, 2020 and 2019. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.

 
Organization

Organization

 

Global WholeHealth Partners Corporation was incorporated on March 7, 2013 in the State of Nevada under the name Texas Jack Oil and Gas Corp. On May 9, 2019, the Company amended its Articles of Incorporation to effect a change of name to Global WholeHealth Partners Corporation to align the company name with its focus on health care related development and products. The Company’s ticker symbol changed to GWHP.

 

The Company was originally organized for the purpose of exploration of Oil and Gas. However, the Company was unable to establish an oil and gas concern and was abandoned in 2016. On February 27, 2019, the Clark County District Court of Nevada appointed Barbara Bauman as custodian to the Company. The custodian reestablished the Company in good standing.

 

On May 9, 2019, the Board reverse split (1-for-500) the outstanding Common Shares of 58,172,000 to 116,358 shares.

 

May 23, 2019, the Company and LionsGate Funding Group LLC (“LionsGate”), owner of a majority of the Company’s outstanding common stock as of May 23, 2019, entered into a Stock Sale and Purchase Agreement (the “SPA”) which closed on June 27, 2019. Pursuant the SPA, the Company issued 56,000,000 shares of common stock to LionsGate in exchange for 100% of their interests in Global WholeHealth Partners Corp., a private Wyoming corporation incorporated on April 9, 2019 (“Global Private”). Global Private has contacts with suppliers and contract manufacturers in the In vitro diagnostic industry, with rights to sell rapid diagnostic tests, such as the following 6 minute rapid whole blood Ebola Test, 6 minute whole blood Zika test, 8 minute whole blood rapid TB test and 75 plus other tests more than 40 which are FDA approved. Due to the common control of the Company and Global Private, pursuant to ASC 805-50-25, “Transactions Between Entities Under Common Control”, the SPA was accounted for as a transfer of the carrying amounts of assets and liabilities under the predecessor value method of accounting. Financial statement presentation under the predecessor values method of accounting as a result of a business combination between entities under common control requires the receiving entity (i.e., the Company) to report the results of operations as if both entities had been combined as of the beginning of the periods presented. The consolidated financial statements include both entities’ full results since the inception of Global Private.
Going Concern

Going Concern

 

The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs to allow it to continue as a going concern. As of March 31, 2020, the Company had an accumulated deficit of $544,607. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

 

In view of these conditions, the ability of the Company to continue as a going concern is in doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. Historically, the Company has relied upon internally generated funds, and funds from the sale of stock, issuance of promissory notes and loans from its shareholders and private investors to finance its operations and growth. Management is planning to raise necessary additional funds for working capital through loans and/or additional sales of its common stock. However, there is no assurance that the Company will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should the Company be unable to raise this amount of capital its operating plans will be limited to the amount of capital that it can access. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements.

XML 29 R10.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholder's Equity
 9 Months Ended
Mar. 31, 2020
Stockholders Equity  
Stockholder’s Equity

NOTE 3 – Stockholder’s Equity

 

Preferred Stock

 

The Company has Preferred stock: $0.001 par value; 10,000,000 shares authorized with no shares issued and outstanding.

 

Common Stock

 

The Company has 400,000,000 shares of Common Stock authorized of which 58,116,358 and 56,116,358 shares were issued and outstanding as of March 31, 2020 and June 30, 2019, respectively. During the nine months ended March 31, 2020, the number of shares increased by 2,000,000 as a result of the Company selling 2,000,000 shares at $0.01 per share to LionsGate in exchange for cash of $20,000.

 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.20.1
Promissory Note (Narrative) (Details) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended
Mar. 30, 2020
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2020
Mar. 31, 2019
Mar. 29, 2020
Short-term Debt [Line Items]              
Research and development expenses   $ 443,750   $ 443,750  
LionsGate Funding Group LLC [Member]              
Short-term Debt [Line Items]              
Research and development expenses   443,750     443,750    
LionsGate Funding Group LLC [Member] | Promissory Note [Member]              
Short-term Debt [Line Items]              
Debt instrument face amount             $ 506,625
Research and development expenses $ 443,750            
Other Income   443,750   $ 443,750      
Debt instrument carrying amount   $ 62,875   $ 62,875 $ 62,875    
Proceeds from issuance of notes payable 585,000            
Additional issuance of notes payable $ 78,375            
Promissory note interest rate 5.00%            
Promissory notes description The Note bears interest at the rate of 5% per annum and the principal and interest is due and payable in full in 90 days on June 30, 2020. If not paid within the 90 days a 5% penalty will be added to the Note and the term will extend for an additional 90 days.            
Promissory notes maturity date Jun. 30, 2020            
XML 31 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 72 178 1 false 6 0 false 4 false false R1.htm 00000001 - Document - Document And Entity Information Sheet http://globalwholehealthpartnerscorporation.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://globalwholehealthpartnerscorporation.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://globalwholehealthpartnerscorporation.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements Of Operations (Unaudited) Sheet http://globalwholehealthpartnerscorporation.com/role/StatementsOfOperations Consolidated Statements Of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements Of Stockholders Deficit (Unaudited) Sheet http://globalwholehealthpartnerscorporation.com/role/StatementsOfStockholdersDeficit Consolidated Statements Of Stockholders Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements Of Stockholders Deficit (Unaudited) (Parenthetical) Sheet http://globalwholehealthpartnerscorporation.com/role/StatementsOfStockholdersDeficitParenthetical Consolidated Statements Of Stockholders Deficit (Unaudited) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements Of Cash Flows (Unaudited) Sheet http://globalwholehealthpartnerscorporation.com/role/StatementsOfCashFlows Consolidated Statements Of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Basis Of Presentation, Organization And Going Concern Sheet http://globalwholehealthpartnerscorporation.com/role/BasisOfPresentationOrganizationAndGoingConcern Basis Of Presentation, Organization And Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Summary Of Significant Accounting Policies Sheet http://globalwholehealthpartnerscorporation.com/role/SummaryOfSignificantAccountingPolicies Summary Of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Stockholder's Equity Sheet http://globalwholehealthpartnerscorporation.com/role/StockholdersEquity Stockholder's Equity Notes 10 false false R11.htm 00000011 - Disclosure - Related Party Transactions Sheet http://globalwholehealthpartnerscorporation.com/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 00000012 - Disclosure - Promissory Note Sheet http://globalwholehealthpartnerscorporation.com/role/PromissoryNote Promissory Note Notes 12 false false R13.htm 00000013 - Disclosure - Subsequent Events Sheet http://globalwholehealthpartnerscorporation.com/role/SubsequentEvents Subsequent Events Notes 13 false false R14.htm 00000014 - Disclosure - Basis of Presentation, Organization And Going Concern (Policies) Sheet http://globalwholehealthpartnerscorporation.com/role/BasisOfPresentationOrganizationAndGoingConcernPolicies Basis of Presentation, Organization And Going Concern (Policies) Policies http://globalwholehealthpartnerscorporation.com/role/SummaryOfSignificantAccountingPolicies 14 false false R15.htm 00000015 - Disclosure - Summary Of Significant Accounting Policies (Policies) Sheet http://globalwholehealthpartnerscorporation.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary Of Significant Accounting Policies (Policies) Policies http://globalwholehealthpartnerscorporation.com/role/SummaryOfSignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Organization (Narrative) (Details) Sheet http://globalwholehealthpartnerscorporation.com/role/OrganizationNarrativeDetails Organization (Narrative) (Details) Details 16 false false R17.htm 00000017 - Disclosure - Related Party Transactions (Narrative) (Details) Sheet http://globalwholehealthpartnerscorporation.com/role/RelatedPartyTransactionsNarrativeDetails Related Party Transactions (Narrative) (Details) Details http://globalwholehealthpartnerscorporation.com/role/RelatedPartyTransactions 17 false false R18.htm 00000018 - Disclosure - Promissory Note (Narrative) (Details) Sheet http://globalwholehealthpartnerscorporation.com/role/PromissoryNoteNarrativeDetails Promissory Note (Narrative) (Details) Details http://globalwholehealthpartnerscorporation.com/role/PromissoryNote 18 false false All Reports Book All Reports gwhp-20200331.xml gwhp-20200331.xsd gwhp-20200331_cal.xml gwhp-20200331_def.xml gwhp-20200331_lab.xml gwhp-20200331_pre.xml http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 32 R15.htm IDEA: XBRL DOCUMENT v3.20.1
Summary Of Significant Accounting Policies (Policies)
 9 Months Ended
Mar. 31, 2020
Disclosure Summary Of Significant Accounting Policies Policies Abstract  
Principles of Consolidation

Principles of Consolidation

 

Global WholeHealth Partners Corp, a private Wyoming corporation was incorporated on April 9, 2019 to receive private investor funds and aggregate certain in vitro diagnostic assets.

 

These consolidated financial statements presented are those of Global WholeHealth Partners Corporation and its wholly owned subsidiary, Global Private. All significant intercompany balances and transactions have been eliminated.
Accounting estimates

Accounting estimates

 

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates.
Cash and cash equivalents

Cash and cash equivalents

 

The Company considers all highly liquid instruments purchased with an original maturity of three months or less and money market accounts to be cash equivalents.

 
Income Taxes

Income Taxes

 

The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively.
Fair Value Measurements

Fair Value Measurements

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilizes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

During the periods covered by this report, the Company did not have any assets or liabilities that were required to be measured at fair value on a recurring basis or on a non-recurring basis.
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company’s financial instruments consist of cash, accounts payable and accrued expenses. The carrying amounts of the Company’s financial instruments approximate fair value because of the short term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect those estimates. We do not hold or issue financial instruments for trading purposes, nor do we utilize derivative instruments.
Net Income (Loss) Per Share

Net Income (Loss) Per Share

 

The computation of basic earnings per share (“EPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common shares that would be issued assuming the exercise of all potentially dilutive common shares outstanding using the treasury stock method. The Company had no potentially dilutive securities as of December 31, 2019.
New Accounting Pronouncements

New Accounting Pronouncements

 

Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification.

 

We review new accounting standards as issued. Although some of these accounting standards issued or effective after the end of our previous fiscal year may be applicable to us, we have not identified any standards that we believe merit discussion. We believe that none of the new standards will have a significant impact on our consolidated financial statements.
XML 33 R11.htm IDEA: XBRL DOCUMENT v3.20.1
Related Party Transactions
 9 Months Ended
Mar. 31, 2020
Related Party Transactions  
Related Party Transactions

NOTE 4 – Related Party Transactions

 

During the nine months ended March 31, 2020, the Company received $20,000 upon the sale of 2,000,000 shares of common stock to LionsGate for $0.01 per share.

 

From time-to-time the Company receives shareholder advances to cover operating costs which are reflected on the balance sheet as related party advances. During the three months ended March 31, 2020, LionsGate provided advances totaling $455,950 which was used to pay professional fees of $11,100, research studies for the development of its CoVid-19 tests of $443,750 and general costs of $1,100. During the nine months ended March 31, 2020, LionsGate provided advances totaling $506,625 which was used to pay professional fees of $46,000, research studies for the development of CoVid-19 tests of $443,750 and general costs of $16,875.

 

During the three months ended March 31, 2020, the Company paid $431,250 to Pan Probe Biotech to perform studies in validation of the Company’s CoVid-19 tests. Dr. Shujie Cui is the Company’s Chief Science Officer and 100% owner of Pan Probe.
XML 34 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 35 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document And Entity Information - shares
 9 Months Ended
Mar. 31, 2020
May 07, 2020
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2020  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2020  
Current Fiscal Year End Date --06-30  
Entity File Number 000-56035  
Entity Registrant Name Global Wholehealth Partners Corp  
Entity Central Index Key 0001598308  
Entity Tax Identification Number 46-2316220  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 2227 Avenida Oliva  
Entity Address, Address Line Two San Clemente, California  
Entity Address, City or Town California  
Entity Address, State or Province NV  
Entity Address, Postal Zip Code 92673  
City Area Code (714)  
Local Phone Number 392-9752  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   58,116,358
XML 36 R5.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements Of Stockholders Deficit (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Deficit [Member]
Total
Balance, common shares at Jun. 30, 2018 52,358      
Balance, amount at Jun. 30, 2018 $ 52 $ 430,748 $ (432,215) $ (1,415)
Net loss (300) (300)
Balance, common shares at Sep. 30, 2018 52,358      
Balance, amount at Sep. 30, 2018 $ 52 430,748 (432,515) (1,715)
Balance, common shares at Jun. 30, 2018 52,358      
Balance, amount at Jun. 30, 2018 $ 52 430,748 (432,215) (1,415)
Net loss       (9,608)
Balance, common shares at Mar. 31, 2019 52,358      
Balance, amount at Mar. 31, 2019 $ 52 430,748 (441,823) (11,023)
Balance, common shares at Sep. 30, 2018 52,358      
Balance, amount at Sep. 30, 2018 $ 52 430,748 (432,515) (1,715)
Net loss (300) (300)
Balance, common shares at Dec. 31, 2018 52,358      
Balance, amount at Dec. 31, 2018 $ 52 430,748 (432,815) (2,015)
Net loss (9,008) (9,008)
Balance, common shares at Mar. 31, 2019 52,358      
Balance, amount at Mar. 31, 2019 $ 52 430,748 (441,823) $ (11,023)
Balance, common shares at Jun. 30, 2019 56,116,358     56,116,358
Balance, amount at Jun. 30, 2019 $ 56,116 426,784 (463,082) $ 19,818
Net loss (18,798) (18,798)
Balance, common shares at Sep. 30, 2019 56,116,358      
Balance, amount at Sep. 30, 2019 $ 56,116 426,784 (481,880) $ 1,020
Balance, common shares at Jun. 30, 2019 56,116,358     56,116,358
Balance, amount at Jun. 30, 2019 $ 56,116 426,784 (463,082) $ 19,818
Net loss       $ (81,525)
Balance, common shares at Mar. 31, 2020 58,116,358     58,116,358
Balance, amount at Mar. 31, 2020 $ 58,116 444,784 (544,607) $ (41,707)
Balance, common shares at Sep. 30, 2019 56,116,358      
Balance, amount at Sep. 30, 2019 $ 56,116 426,784 (481,880) 1,020
Common stock issued to related party for cash at $0.01 per share, shares 2,000,000      
Common stock issued to related party for cash at $0.01 per share, amount $ 2,000 18,000 20,000
Net loss (51,098) (51,098)
Balance, common shares at Dec. 31, 2019 58,116,358      
Balance, amount at Dec. 31, 2019 $ 58,116 444,784 (532,978) (30,078)
Net loss (11,629) $ (11,629)
Balance, common shares at Mar. 31, 2020 58,116,358     58,116,358
Balance, amount at Mar. 31, 2020 $ 58,116 $ 444,784 $ (544,607) $ (41,707)
XML 37 R9.htm IDEA: XBRL DOCUMENT v3.20.1
Summary Of Significant Accounting Policies
 9 Months Ended
Mar. 31, 2020
Summary Of Significant Accounting Policies  
Summary of Significant Accounting Policies

NOTE 2 – Summary of Significant Accounting Policies

 

Principles of Consolidation

 

Global WholeHealth Partners Corp, a private Wyoming corporation was incorporated on April 9, 2019 to receive private investor funds and aggregate certain in vitro diagnostic assets.

 

These consolidated financial statements presented are those of Global WholeHealth Partners Corporation and its wholly owned subsidiary, Global Private. All significant intercompany balances and transactions have been eliminated.

 

Accounting estimates

 

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates.

 

Cash and cash equivalents

 

The Company considers all highly liquid instruments purchased with an original maturity of three months or less and money market accounts to be cash equivalents.

 

Income Taxes

 

The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively.

 

Fair Value Measurements

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilizes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

During the periods covered by this report, the Company did not have any assets or liabilities that were required to be measured at fair value on a recurring basis or on a non-recurring basis.

 

Fair Value of Financial Instruments

 

The Company’s financial instruments consist of cash, accounts payable and accrued expenses. The carrying amounts of the Company’s financial instruments approximate fair value because of the short term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect those estimates. We do not hold or issue financial instruments for trading purposes, nor do we utilize derivative instruments.

 

Net Income (Loss) Per Share

 

The computation of basic earnings per share (“EPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common shares that would be issued assuming the exercise of all potentially dilutive common shares outstanding using the treasury stock method. The Company had no potentially dilutive securities as of December 31, 2019.

 

New Accounting Pronouncements

 

Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification.

 

We review new accounting standards as issued. Although some of these accounting standards issued or effective after the end of our previous fiscal year may be applicable to us, we have not identified any standards that we believe merit discussion. We believe that none of the new standards will have a significant impact on our consolidated financial statements.
XML 38 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; }